Browsing Clinical Studies by author "Au, Lewis"
Now showing items 1-13 of 13
-
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
Gudd, CLC; Au, L; Triantafyllou, E; Shum, B; Liu, T; et al. (ELSEVIER, 2021-07-01)BACKGROUND & AIMS: Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid ... -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27)Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients ... -
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
O'Reilly, A; Hughes, P; Mann, J; Lai, Z; Teh, JJ; et al. (SPRINGER, 2020-02-01)PURPOSE: The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with metastatic melanoma achieving high-quality durable responses. Metastatic melanoma survivors are a new population in the era of ... -
Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients
Au, L (Institute of Cancer Research (University Of London), 2022-04-30)The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic ... -
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; et al. (CELL PRESS, 2018-04-19)The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ... -
Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
Favara, DM; Spain, L; Au, L; Clark, J; Daniels, E; et al. (ELSEVIER, 2020-07-01)BACKGROUND: Immune-related diarrhoea/colitis (ir-D/C) is a common adverse event of immune checkpoint inhibitor (ICI) therapy. Guidelines recommend corticosteroid (CS) treatment; however, the average treatment duration for ... -
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; et al. (NATURE PORTFOLIO, 2021-09-20)Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were ... -
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Litchfield, K; Stanislaw, S; Spain, L; Gallegos, LL; Rowan, A; et al. (CELL PRESS, 2020-05-05)Although thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm biopsy), which ... -
Selection of metastasis competent subclones in the tumour interior.
Zhao, Y; Fu, X; Lopez, JI; Rowan, A; Au, L; et al. (NATURE PORTFOLIO, 2021-05-17)The genetic evolutionary features of solid tumour growth are becoming increasingly well described, but the spatial and physical nature of subclonal growth remains unclear. Here, we utilize 102 macroscopic whole-tumour ... -
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.
Fu, X; Zhao, Y; Lopez, JI; Rowan, A; Au, L; et al. (NATURE PORTFOLIO, 2022-01-01)Genetic intra-tumour heterogeneity fuels clonal evolution, but our understanding of clinically relevant clonal dynamics remain limited. We investigated spatial and temporal features of clonal diversification in clear cell ... -
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.
Mitchell, TJ; Turajlic, S; Rowan, A; Nicol, D; Farmery, JHR; et al. (CELL PRESS, 2018-04-19)Clear cell renal cell carcinoma (ccRCC) is characterized by near-universal loss of the short arm of chromosome 3, deleting several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with ... -
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.
Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Chambers, T; et al. (CELL PRESS, 2018-04-19)Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with ...